Company Filing History:
Years Active: 2018
Title: Eliran-Moshe Reuven: Innovator in Toll-like Receptor Research
Introduction: Eliran-Moshe Reuven is a prominent inventor based in Rehovot, Israel, known for his groundbreaking work in the field of immunology. He has contributed significantly to the development of therapeutic peptides aimed at treating diseases mediated by Toll-like receptors (TLRs). With one patent to his name, Reuven is recognized for his innovative approach to tackling critical medical challenges.
Latest Patents: Reuven holds a patent for "Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases." This patent details novel peptides designed to inhibit cell activation mediated by TLRs, specifically TLR 1, 2, 4, or 6. The peptides consist of sequences sourced from the transmembrane domain of these receptors, along with potential cytoplasmic and extracellular regions. The pharmaceutical compositions that incorporate these peptides are positioned as promising treatments for a range of TLR-mediated ailments.
Career Highlights: Eliran-Moshe Reuven's career has been marked by a dedication to research and innovation in the realm of immunology. He is currently affiliated with Yeda Research and Development Co. Ltd., a leading organization known for its commitment to advancing scientific research and commercializing innovative solutions. Reuven's work has garnered attention for its potential to transform the treatment of diseases that involve TLR-mediated signaling pathways.
Collaborations: Throughout his career, Reuven has collaborated with esteemed colleagues, including Yechiel Shai and Avner Fink. These collaborations have undoubtedly contributed to enhancing the depth and impact of his research in the field of TLRs, fostering an environment of innovation and scientific advancement.
Conclusion: Eliran-Moshe Reuven stands out as a notable inventor whose work is paving the way for new therapeutic approaches to TLR-mediated diseases. With his innovative peptide design and significant collaboration efforts, he continues to contribute valuable knowledge and solutions to the field of immunology. His achievements exemplify the importance of innovation in addressing complex medical challenges.